JPRN-UMIN000020075招募中2 期
Phase II Randomized Radiation Dose Study of Concurrent Chemoradiotherapy With S-1 Plus Nedaplatin for Esophageal Cancer - Radiation Dose Study of CCRT with S-1 / NDP for Esophageal Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •a) with active gastrointestinal hemorrhage b) with clinically important infection c) with severe complicatons (heart failure, renal failure, liver failure, uncontrollable diabetes, etc.) d) with another active malignant tumors e) pregnant and/or lactating women f) judged not to understand the trial explanation g) judged to be unfit to participate in this study by investigater
研究者
相似试验
进行中（未招募）
不适用
Étude de phase II randomisée évaluant une irradiation pelvienne associée au Cisplatine seul ou au Cisplatine plus Cetuximab chez des patientes présentant un carcinome du col utérin de stade IB2, II et III. - CETUXICOPatientes présentant un cancer du col de l’utérus de type épidermoïde ou adénocarcinome de stade Ib2 à IIIb, non antérieurement traitées.EUCTR2008-001053-18-FRINSTITUT CURIE
进行中（未招募）
2 期
RADPLAT for maxillary sinus cancermaxillary sinus cancer, head and neck cancerD008444maxillary sinus cancerJPRN-jRCTs031180425Tanaka Norimitsu44
进行中（未招募）
1 期
a research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-risk localized or locally-advanced cancer, who receive this treatment after initial radical prostatectomy or as primary therapy.very high risk localized or locally advanced prostate cancerMedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005098-19-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)885
进行中（未招募）
1 期
a research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-risk localized or locally-advanced cancer, who receive this treatment after initial radical prostatectomy or as primary therapy.EUCTR2015-005098-19-ITEORTC AISBL/IVZW885
进行中（未招募）
1 期
a research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with locally advanced prostate cancer.EUCTR2015-005098-19-ESEuropean Organisation for Research and Treatment of Cancer (EORTC)885